| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Dirk de Korte | Q55482940 |
| Laura Gutiérrez | Q55692567 | ||
| Pieter F van der Meer | Q56854413 | ||
| P2093 | author name string | Jerard Seghatchian | |
| Vishal Salunkhe | |||
| P2860 | cites work | LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets | Q87177193 |
| Continuous quinacrine treatment results in the formation of drug-resistant prions | Q21090510 | ||
| The influence of riboflavin photochemistry on plasma coagulation factors | Q24614152 | ||
| Innovation in detection of microparticles and exosomes | Q26852941 | ||
| Neutralizing Viruses in Suspensions by Copper Oxide-Based Filters | Q27480797 | ||
| Copper as a biocidal tool | Q28267347 | ||
| Pathogen inactivation technologies for cellular blood components: an update | Q28655769 | ||
| In-gel digestion for mass spectrometric characterization of proteins and proteomes | Q29547583 | ||
| Ebola virus convalescent blood products: where we are now and where we may need to go. | Q30369241 | ||
| The platelet microparticle proteome | Q30438273 | ||
| Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial | Q33345486 | ||
| Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial | Q33360736 | ||
| Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. | Q33368170 | ||
| A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology | Q33389725 | ||
| Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system | Q33397396 | ||
| Bacterial contamination of blood components | Q33719334 | ||
| Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease | Q33933969 | ||
| Viral inactivation of fresh frozen plasma | Q33992794 | ||
| Isolation and characterization of platelet-derived extracellular vesicles | Q34018025 | ||
| CLEC-2 expression is maintained on activated platelets and on platelet microparticles. | Q34284335 | ||
| Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light | Q34322353 | ||
| Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates | Q34423678 | ||
| Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells | Q34436476 | ||
| Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. | Q34565186 | ||
| Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation | Q34660102 | ||
| Emerging infectious disease agents and their potential threat to transfusion safety | Q34997865 | ||
| UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma | Q35095651 | ||
| The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma | Q35095666 | ||
| The quality of platelets after storage for 7 days | Q35184743 | ||
| Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases | Q35561960 | ||
| Assessment of the viral safety of antivenoms fractionated from equine plasma. | Q35944722 | ||
| Adverse effects of plasma transfusion | Q35972184 | ||
| Protecting the blood supply from emerging pathogens: the role of pathogen inactivation | Q36106339 | ||
| Deactivation of human immunodeficiency virus type 1 in medium by copper oxide-containing filters | Q36425078 | ||
| The use of fresh whole blood in massive transfusion | Q36501118 | ||
| Pathogen-reduction systems for blood components: the current position and future trends | Q36655451 | ||
| Proteomics of blood-based therapeutics: a promising tool for quality assurance in transfusion medicine | Q36828037 | ||
| Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies | Q37026225 | ||
| Pathogen reduction of blood components | Q37207560 | ||
| Transfusion-transmitted infectious diseases | Q37397408 | ||
| Proteomics meets blood banking: identification of protein targets for the improvement of platelet quality | Q37580328 | ||
| Clinical trials for pathogen reduction in transfusion medicine: a review | Q37606107 | ||
| Quinacrine promotes replication and conformational mutation of chronic wasting disease prions | Q37725318 | ||
| Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. | Q37903671 | ||
| Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update | Q37988224 | ||
| Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion | Q38130338 | ||
| Transfusion guidelines: when to transfuse. | Q38169694 | ||
| The emerging roles of microvesicles in liver diseases | Q38184831 | ||
| Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands | Q38469282 | ||
| Prion inhibition with multivalent PrPSc binding compounds | Q39322462 | ||
| Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates | Q39725749 | ||
| Development of a riboflavin and ultraviolet light-based device to treat whole blood | Q42278634 | ||
| Removal of TSE agent from plasma products manufactured in the United Kingdom | Q42285664 | ||
| Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. | Q42456722 | ||
| Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light | Q42982277 | ||
| Red cell changes during storage | Q43014508 | ||
| The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model | Q43055573 | ||
| Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products | Q43186766 | ||
| INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function--an in vitro analysis | Q43283190 | ||
| A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light | Q43291668 | ||
| First Ebola treatment is approved by WHO. | Q44093419 | ||
| Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation | Q44827919 | ||
| Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter | Q45258192 | ||
| The proteome of erythrocyte-derived microparticles from plasma: new clues for erythrocyte aging and vesiculation | Q45266579 | ||
| A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. | Q46075116 | ||
| Meta‐analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen‐reduced platelets | Q46115563 | ||
| RBC-derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components | Q46267871 | ||
| Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. | Q46292960 | ||
| Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients | Q46791436 | ||
| Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage | Q46791439 | ||
| Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants | Q46902802 | ||
| Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials | Q47799625 | ||
| Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time | Q47947475 | ||
| Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration | Q48355452 | ||
| Anaphylactic reaction after methylene blue-treated plasma transfusion | Q50282936 | ||
| Anaphylactic shock to fresh‐frozen plasma inactivated with methylene blue | Q50443306 | ||
| Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. | Q50454622 | ||
| Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. | Q50499084 | ||
| Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model. | Q50515465 | ||
| Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. | Q50536784 | ||
| A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. | Q50542143 | ||
| In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. | Q50547235 | ||
| In vitro assessment of red-cell concentrates in SAG-M filtered through the MacoPharma P-CAPT prion-reduction filter. | Q50604353 | ||
| The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components. | Q50740089 | ||
| Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. | Q51540517 | ||
| Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies. | Q51763978 | ||
| Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. | Q51787809 | ||
| Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. | Q53877861 | ||
| Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light. | Q54200365 | ||
| Transfusion-transmitted bacterial infection in the United States, 1998 through 2000 | Q64128628 | ||
| Viral safety of solvent/detergent-treated plasma | Q73378230 | ||
| Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients | Q77451463 | ||
| Current strategies for the provision of safer plasma and its derivatives: an update | Q77642083 | ||
| FDA approach to evaluation of pathogen reduction technology | Q79079817 | ||
| Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004 | Q83314801 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 19-34 | |
| P577 | publication date | 2014-12-30 | |
| P1433 | published in | Transfusion and Apheresis Science | Q15758507 |
| P1476 | title | Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands | |
| P478 | volume | 52 |
| Q36068943 | 2015 proceedings of the National Heart, Lung, and Blood Institute's State of the Science in Transfusion Medicine symposium. |
| Q33429565 | A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial |
| Q38637507 | Advances in multiplex nucleic acid diagnostics for blood-borne pathogens: promises and pitfalls |
| Q38822804 | Aging of platelets stored for transfusion |
| Q41970183 | Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality |
| Q38750230 | An effective and potentially safe blood disinfection protocol using tetrapyrrolic photosensitizers |
| Q38644253 | An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful? |
| Q90365307 | Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets |
| Q40318288 | Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. |
| Q39148796 | Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma |
| Q36113225 | Development of High Hydrostatic Pressure Applied in Pathogen Inactivation for Plasma |
| Q50210403 | Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation and thrombus stability on collagen. |
| Q51725959 | Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation. |
| Q50219068 | Identification of potential protein quality markers in pathogen inactivated and gamma-irradiated red cell concentrates |
| Q50433573 | Influence of early irradiation on in vitro red blood cell (RBC) storage variables of leucoreduced RBCs in additive solution SAG-M. |
| Q24261277 | Maintaining a Safe Blood Supply in an Era of Emerging Pathogens |
| Q48339584 | Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates |
| Q38369706 | Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views |
| Q38961878 | Optimization of Pathogen Capture in Flowing Fluids with Magnetic Nanoparticles |
| Q33841435 | Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? |
| Q89184302 | Pathogen-Inaktivierungssysteme für Thrombozytenkonzentrate : Stellungnahme |
| Q92591222 | Phased implementation of pathogen-reduced platelets in a health system facilitates increased manufacturing at the blood center |
| Q26740490 | Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future |
| Q38628454 | Platelet microparticles in cryopreserved platelets: Potential mediators of haemostasis |
| Q28733459 | Prevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivation |
| Q53091893 | Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment. |
| Q40324501 | Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. |
| Q36283203 | Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion |
| Q93334682 | Role of transfusions in the development of hospital-acquired urinary tract-related bloodstream infection among United States Veterans |
| Q38784133 | Safety surveillance in haemophilia and allied disorders |
| Q38834645 | Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine |
| Q88720571 | Special considerations for the use of pathogen reduced blood components in pediatric patients: An overview |
| Q57024158 | Towards increasing shelf life and haemostatic potency of stored platelet concentrates |
| Q29994506 | Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries |
| Q31056026 | Transfusion practices and infectious risks |
| Q39367491 | Transfusion-related immunomodulation and cancer |
| Q54977038 | Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets. |
| Q38559443 | Unresolved clinical aspects and safety hazards of blood derived- EV/MV in stored blood components: From personal memory lanes to newer perspectives on the roles of EV/MV in various biological phenomena |
| Q91311984 | Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past |
| Q38831832 | Will pathogen reduction of blood components harm more people than it helps in developed countries? |
Search more.